

Sundar Jagannath

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8586330/sundar-jagannath-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

272
papers

16,466
citations

42
h-index

127
g-index

292
ext. papers

20,416
ext. citations

4.9
avg, IF

5.81
L-index

#	Paper	IF	Citations
272	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology, The</i> , 2014 , 15, e538-48	21.7	2253
271	A phase 2 study of bortezomib in relapsed, refractory myeloma. <i>New England Journal of Medicine</i> , 2003 , 348, 2609-17	59.2	2196
270	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology, The</i> , 2016 , 17, e328-e346	21.7	1155
269	Initial genome sequencing and analysis of multiple myeloma. <i>Nature</i> , 2011 , 471, 467-72	50.4	1117
268	An inflammatory cytokine signature predicts COVID-19 severity and survival. <i>Nature Medicine</i> , 2020 , 26, 1636-1643	50.5	895
267	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011 , 117, 4691-5	2.2	681
266	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2010 , 116, 679-86	2.2	680
265	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019 , 380, 1726-1737	59.2	672
264	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. <i>Leukemia</i> , 2012 , 26, 149-57	10.7	580
263	A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. <i>Blood</i> , 2012 , 120, 2817-25	2.2	544
262	Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3113-20	2.2	529
261	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. <i>Blood</i> , 2014 , 123, 1826-32	2.2	271
260	Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. <i>Haematologica</i> , 2013 , 98, 1753-61	6.6	267
259	Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019 , 381, 727-738	59.2	266
258	Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1953-9	2.2	244
257	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011 , 117, 6063-73	2.2	234
256	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. <i>Blood</i> , 2014 , 123, 1461-9	2.2	152

255	Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017 , 23, 3307-3315	12.9	148
254	Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3196-203	2.2	139
253	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. <i>Lancet Haematology, the</i> , 2015 , 2, e516-27	14.6	129
252	A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015 , 21, 4055-61	12.9	126
251	Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. <i>Blood</i> , 2016 , 127, 2561-8	2.2	121
250	A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2013 , 161, 357-66	4.5	120
249	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <i>Lancet, The</i> , 2021 , 398, 314-324	4.0	118
248	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2039-2051	4.7	114
247	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 859-866	2.2	100
246	An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 310-8	2	97
245	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2020 , 396, 1563-1573	4.0	92
244	A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2012 , 159, 58-66	4.5	92
243	Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. <i>Cancer Cell</i> , 2021 , 39, 1028-1030	24.3	81
242	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 94	22.4	76
241	Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2008 , 143, 537-40	4.5	74
240	Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM). <i>Blood</i> , 2019 , 134, 577-577	2.2	69
239	Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018 , 36, 812-818	2.2	69
238	Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8503-8503	2.2	68

237	State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings. <i>European Journal of Radiology</i> , 2014 , 83, 2203-2223	4.7	61
236	Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 372-380	2	48
235	Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8505-8505	2.2	47
234	Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma. <i>Blood</i> , 2016 , 128, 4486-4486	2.2	45
233	bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8007-8007	2.2	45
232	CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020 , 136, 22-25	2.2	44
231	An inflammatory cytokine signature helps predict COVID-19 severity and death 2020 ,		43
230	A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 29-34	2	41
229	Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes. <i>Blood</i> , 2020 , 136, 25-26	2.2	39
228	BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity. <i>Blood</i> , 2012 , 120, 4042-4042	2.2	36
227	Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. <i>Haematologica</i> , 2014 , 99, e162-4	6.6	33
226	REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020 , 136, 41-42	2.2	32
225	A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. <i>Blood Advances</i> , 2017 , 1, 1575-1583	7.8	31
224	First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3010-3010	2.2	31
223	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020 , 34, 2430-2440	10.7	30
222	Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib. <i>Blood</i> , 2014 , 124, 4736-4736	2.2	29
221	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. <i>Blood Cancer Discovery</i> , 2020 , 1, 234-243	7	29
220	Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies. <i>Frontiers in Immunology</i> , 2018 , 9, 2616	8.4	29

219	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 450-464	12.9	28
218	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. <i>Cancer Cell</i> , 2021 , 39, 1442-1444	24.3	25
217	BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011 , 118, 305-305	2.2	24
216	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. <i>British Journal of Haematology</i> , 2018 , 180, 821-830	4.5	23
215	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. <i>British Journal of Haematology</i> , 2018 , 182, 495-503	4.5	23
214	VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 329-334.e1	2	22
213	Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. <i>Blood Advances</i> , 2018 , 2, 1470-1479	7.8	22
212	Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019 , 134, 3176-3176	2.2	21
211	Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression. <i>Blood</i> , 2012 , 120, 331-331	2.2	21
210	Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. <i>Blood</i> , 2016 , 128, 491-491	2.2	20
209	Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2018 , 124, 4342-4349	6.4	20
208	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. <i>Blood Cancer Journal</i> , 2021 , 11, 10	7	20
207	Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study. <i>Blood</i> , 2020 , 136, 26-27	2.2	19
206	Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 480-485.e3	2	19
205	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 555-562	2	18
204	Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset. <i>Blood</i> , 2019 , 134, 928-928	2.2	18
203	Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients. <i>Blood</i> , 2013 , 122, 758-758	2.2	18
202	Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. <i>Cancer Research</i> , 2016 , 76, 1225-36	10.1	17

201	Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019 , 134, 140-140	2.2	16
200	First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020 , 136, 16-17	2.2	16
199	A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8021-8021	2.2	16
198	SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 537-544	2	15
197	Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220). <i>Blood</i> , 2019 , 134, 3119-3119	2.2	15
196	Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 632-636.e1	2	15
195	A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM). <i>Blood</i> , 2019 , 134, 3116-3116	2.2	14
194	Interim Analysis Of The Mmrf Compass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles. <i>Blood</i> , 2013 , 122, 532-532	2.2	14
193	ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM). <i>Blood</i> , 2013 , 122, 759-759	2.2	14
192	A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma. <i>Blood</i> , 2015 , 126, 4226-4226	2.2	14
191	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia 2016 , 4, 90		14
190	Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2510-5	1.9	12
189	Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up. <i>Blood</i> , 2010 , 116, 3049-3049	2.2	12
188	A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. <i>Blood</i> , 2012 , 120, 202-202	2.2	12
187	A phase 1b study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8539-8539	2.2	12
186	Ciltacabtagene autoleucl, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8005-8005	2.2	12
185	Adverse drug reaction: pomalidomide-induced liver injury. <i>Lancet, The</i> , 2014 , 383, 2125-6	40	11
184	Rocilinstat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study. <i>Blood</i> , 2012 , 120, 4061-4061	2.2	11

183	Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2014 , 124, 302-302	2.2	11
182	Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8016-8016	2.2	11
181	KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8525-8525	2.2	11
180	Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 351-357	2	10
179	Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. <i>Blood</i> , 2011 , 118, 1876-1876	2.2	10
178	Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , 2014 , 124, 4764-4764	2.2	10
177	Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8542-8542	2.2	10
176	Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. <i>Science Advances</i> , 2021 , 7, eabg9551	14.3	10
175	KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021 , 11, 116	7	10
174	Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	10
173	Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8543-8543	2.2	9
172	Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021 , 138, 651-651	2.2	9
171	Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2021 , 138, 548-548	2.2	9
170	Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021 , 138, 549-549	2.2	9
169	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021 , 96, 708-718	7.18	9
168	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. <i>American Journal of Hematology</i> , 2021 , 96, E5-E8	7.1	9
167	Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. <i>Nature Medicine</i> , 2021 ,	50.5	8
166	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. <i>Blood</i> , 2012 , 120, 450-450	2.2	8

165	Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results. <i>Blood</i> , 2014 , 124, 31-31	2.2	8
164	Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8014-8014	2.2	8
163	Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. <i>Expert Review of Hematology</i> , 2020 , 13, 943-958	2.8	8
162	Bispecific Antibodies in Multiple Myeloma: Present and Future. <i>Blood Cancer Discovery</i> , 2021 , 2, 423-433	7	8
161	Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 663-677	2.9	7
160	Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. <i>Blood</i> , 2020 , 136, 16-17	2.2	7
159	Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study. <i>Blood</i> , 2014 , 124, 303-303	2.2	7
158	Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition. <i>Blood</i> , 2014 , 124, 3445-3445	2.2	7
157	Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2021 , 138, 160-160	2.2	7
156	Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis. <i>Cancer</i> , 2020 , 126, 4332-4340	6.4	7
155	Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2016 , 9, 91-105	2.8	6
154	Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. <i>Clinical Therapeutics</i> , 2018 , 40, 1193-1202.e1	3.5	6
153	Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 356-69	2	6
152	Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 680-6	2	6
151	Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM). <i>Blood</i> , 2010 , 116, 1954-1954	2.2	6
150	Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , 2010 , 116, 985-985	2.2	6
149	Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study. <i>Blood</i> , 2016 , 128, 194-194	2.2	6
148	Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect MM Registry. <i>Blood</i> , 2016 , 128, 4489-4489	2.2	6

147	The effect of novel therapies in high-molecular-risk multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2017 , 15, 870-879	0.6	6
146	Connect MM Registry as a national reference for United States multiple myeloma patients. <i>Cancer Medicine</i> , 2020 , 9, 35-42	4.8	6
145	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 59	22.4	6
144	A phase II trial of TBL-12 sea cucumber extract in patients with untreated asymptomatic myeloma. <i>British Journal of Haematology</i> , 2018 , 180, 296-298	4.5	6
143	Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 541-5	2	5
142	Asymptomatic monoclonal gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14 Suppl, S78-86	2	5
141	Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020 , 136, 41-42	2.2	5
140	Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial. <i>Blood</i> , 2010 , 116, 862-862	2.2	5
139	KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS8070-TPS8070	2.2	5
138	Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8024-8024	2.2	5
137	COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers 2020 ,		5
136	Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. <i>Cancer</i> , 2021 , 127, 1816-1826	6.4	5
135	The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution. <i>Cancer Medicine</i> , 2016 , 5, 500-5	4.8	5
134	A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2021 , 14, 31-45	2.8	5
133	Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. <i>Blood Advances</i> , 2021 , 5, 367-376	7.8	5
132	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. <i>American Journal of Hematology</i> , 2021 , 96, 1120-1130	7.1	5
131	Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. <i>Blood</i> , 2019 , 134, 1854-1854	2.2	4
130	Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020 , 136, 13-15	2.2	4

129	A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011 , 118, 303-303	2.2	4
128	Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2013 , 122, 3220-3220 ^{2,3}	2.2	4
127	A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat In Combination With Lenalidomide and Weekly Dexamethasone In Patients With Multiple Myeloma. <i>Blood</i> , 2013 , 122, 5392-5392 ^{3,2}	2.2	4
126	KEYNOTE-185: a randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS8069-TPS8069	2.2	4
125	Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 272-276	2	4
124	Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2021 , 12, 2040620720987075	5.7	4
123	Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. <i>Lancet Haematology</i> , 2021 , 8, e794-e807 ^{14,6}	14.6	4
122	Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study. <i>Blood</i> , 2020 , 136, 45-46	2.2	3
121	Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM). <i>Blood</i> , 2010 , 116, 3031-3031	2.2	3
120	BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2010 , 116, 3060-3060 ^{2,2}	2.2	3
119	Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study. <i>Blood</i> , 2010 , 116, 986-986	2.2	3
118	Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM). <i>Blood</i> , 2011 , 118, 631-631	2.2	3
117	A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma. <i>Blood</i> , 2013 , 122, 3181-3181	2.2	3
116	A Phase II, Single-Center, Open-Label Study of Oral Panobinostat in Combination with Lenalidomide and Weekly Dexamethasone in Patients with Multiple Myeloma. <i>Blood</i> , 2014 , 124, 3486-3486	2.2	3
115	A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2016 , 128, 4520-4520	2.2	3
114	Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8532-8532	2.2	3
113	A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8528-8528	2.2	3
112	Impact of t(11;14) on outcomes in African American (AA) and non-AA (NAA) patients (Pts) with newly diagnosed multiple myeloma (NDMM): Connect MM registry.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8023-8023	2.2	3

111	Ciltacabtagene Autoleucl for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study. <i>Blood</i> , 2021 , 138, 550-550	2.2	3
110	Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T. <i>Blood</i> , 2021 , 138, 2704-2704	2.2	3
109	Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial. <i>Blood</i> , 2021 , 138, 162-162	2.2	3
108	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward 2020 ,		3
107	Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients. <i>Blood</i> , 2010 , 116, 1938-1938	2.2	3
106	Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, e470-e476	2	3
105	Selinexor for the treatment of patients with previously treated multiple myeloma. <i>Expert Review of Hematology</i> , 2021 , 14, 697-706	2.8	3
104	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2020 , 127, 82-92	6.4	3
103	Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 693-702	2	3
102	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucl in CARTITUDE studies.. <i>Blood Cancer Journal</i> , 2022 , 12, 32	7	3
101	Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients.. <i>Cancer Cell</i> , 2022 ,	24.3	3
100	Monoclonal Gammopathy May Be of Unpredictable Significance. <i>JAMA Oncology</i> , 2019 , 5, 1302-1303	13.4	2
99	Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2959-61 ⁹		2
98	Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program. <i>Blood</i> , 2010 , 116, 1952-1952	2.2	2
97	Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM). <i>Blood</i> , 2010 , 116, 1953-1953	2.2	2
96	The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.. <i>Blood</i> , 2010 , 116, 3803-3803	2.2	2
95	A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,. <i>Blood</i> , 2011 , 118, 3971-3971	2.2	2
94	Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM. <i>Blood</i> , 2011 , 118, 813-813	2.2	2

93	Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study. <i>Blood</i> , 2014 , 124, 2119-2119	2.2	2
92	Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib. <i>Blood</i> , 2015 , 126, 3051-3051	2.2	2
91	Flow Cytometry Based Detection of MRD in Bone Marrow of Patients with Multiple Myeloma: A Comparison Between Fluorescent-Based Cytometry Versus Cytof. <i>Blood</i> , 2015 , 126, 4195-4195	2.2	2
90	MAGE-a Mediate Resistance to Chemotherapy in Multiple Myeloma through Regulation of Bcl-2 Proteins. <i>Blood</i> , 2016 , 128, 3277-3277	2.2	2
89	A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8020-8020	2.2	2
88	Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001. <i>Blood</i> , 2020 , 136, 8-9	2.2	2
87	Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis. <i>Blood</i> , 2021 , 138, 3938-3938	2.2	2
86	Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma. <i>Annals of Hematology</i> , 2021 , 100, 3057-3060	3	2
85	Where you live can impact your cancer risk: a look at multiple myeloma in New York City. <i>Annals of Epidemiology</i> , 2020 , 48, 43-50.e4	6.4	2
84	A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2208-2215	1.9	2
83	Characteristics of neurotoxicity associated with idcabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8036-8036	2.2	2
82	Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect MM Registry. <i>British Journal of Haematology</i> , 2021 , 193, 93-100	4.5	2
81	Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. <i>EJHaem</i> , 2021 , 2, 48-55	0.9	2
80	Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e734-e751	2	1
79	Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab. <i>Blood</i> , 2020 , 136, 6-7	2.2	1
78	Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations. <i>Blood</i> , 2020 , 136, 9-10	2.2	1
77	E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients. <i>Blood</i> , 2018 , 132, 3216-3216	2.2	1
76	Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma. <i>Blood</i> , 2018 , 132, 59-59	2.2	1

75	Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect MM Registry. <i>Blood</i> , 2019 , 134, 3129-3129	2.2	1
74	Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance. <i>Blood</i> , 2019 , 134, 1779-1779	2.2	1
73	Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg FISH) Enhances the Quantitative Detection of Chromosome Abnormalities In Plasma Cell Neoplasms Compared to Conventional FISH. <i>Blood</i> , 2010 , 116, 1198-1198	2.2	1
72	Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study. <i>Blood</i> , 2010 , 116, 1936-1936	2.2	1
71	A 28 Day Schedule for Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2011 , 118, 2949-2949	2.2	1
70	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure. <i>Blood</i> , 2012 , 120, 4070-4070	2.2	1
69	A Comparison of the Outcomes of Early Versus Delayed Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies. <i>Blood</i> , 2015 , 126, 1993-1993	2.2	1
68	Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Compass Study. <i>Blood</i> , 2015 , 126, 722-722	2.2	1
67	Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma. <i>Blood</i> , 2016 , 128, 3448-3448	2.2	1
66	Network Modeling Reveals CDC42BPA and CLEC11A As Novel Driver Genes of t(4; 14) Multiple Myeloma. <i>Blood</i> , 2016 , 128, 802-802	2.2	1
65	Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8040-8040	2.2	1
64	Treatment patterns in multiple myeloma: Real-world experience of the triple-class exposed (TCE) patient.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e20543-e20543	2.2	1
63	Digital Health for Patients With Multiple Myeloma: An Unmet Need. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 1096-1105	5.2	1
62	Anakinra Targeting Cytokine Release Syndrome Associated with Chimeric Antigen Receptor T-Cell Therapies. <i>Blood</i> , 2021 , 138, 2812-2812	2.2	1
61	Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial. <i>Blood</i> , 2021 , 138, 1739-1739	2.2	1
60	Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. <i>Clinical Drug Investigation</i> , 2021 , 1	3.2	1
59	Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs). <i>Blood</i> , 2021 , 138, 821-821	2.2	1
58	Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Ibrandomide-Treated Myeloma Patients. <i>Blood</i> , 2021 , 138, 730-730	2.2	1

57	Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1658-1658	2.2	1
56	Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 326-326	2.2	1
55	Healthcare Costs Incurred by Patients with Multiple Myeloma Following Triple Class Exposure (TCE) in the US. <i>Oncology and Therapy</i> , 2021 , 9, 659-669	2.7	1
54	Quality-of-life (QOL) analyses in patients with multiple myeloma: Results from the selinexor (KPT-330) treatment of refractory myeloma (STORM) phase IIb study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e20522-e20522	2.2	1
53	A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results. <i>Blood</i> , 2012 , 120, 4058-4058	2.2	1
52	Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8024-8024	2.2	1
51	Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8045-8045	2.2	1
50	Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, e975-e984	2	1
49	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. <i>American Journal of Hematology</i> , 2021 , 96, E383-E386	7.1	1
48	Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e341-e344	2	0
47	Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE) for Multiple Myeloma (MM) Digital Solution in Patients with MM. <i>Blood</i> , 2020 , 136, 3-4	2.2	0
46	Targeting Nuclear Export Proteins in Multiple Myeloma Therapy.. <i>BioDrugs</i> , 2022 , 36, 13	7.9	0
45	Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8588-8588	2.2	0
44	Total Car-T Cost of Care Beyond the Price of Car-T Cell Therapy in Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 4964-4964	2.2	0
43	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. <i>Blood</i> , 2021 , 138, 3793-3793	2.2	0
42	A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma. <i>Blood</i> , 2019 , 134, 3101-3101	2.2	0
41	Patient characteristics and treatment patterns in relapsed/refractory multiple myeloma patients after exposure to a proteasome inhibitor, an immunomodulatory agent and daratumumab.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e20540-e20540	2.2	0
40	Integrative Network Analysis of Newly Diagnosed Multiple Myeloma Identifies a Novel RNA-Seq Based High Riskgene Signature. <i>Blood</i> , 2016 , 128, 3285-3285	2.2	0

39	Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. <i>EJHaem</i> , 2022 , 3, 97-108	0.9	0
38	Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study. <i>Blood</i> , 2020 , 136, 48-50	2.2	
37	28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2020 , 136, 13-13	2.2	
36	Title: Genomic and Systemic Metabolism Differences Associated with Racial Disparities in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1601-1601	2.2	
35	Cost per Responder Analysis to Assess the Value of CAR-T Therapy for Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2021 , 138, 4961-4961	2.2	
34	Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). <i>Blood</i> , 2021 , 138, 1634-1634	2.2	
33	Triple MAPK Inhibition Salvaged a Relapsed Post BCMA CAR-T Cell Therapy in Multiple Myeloma Patient with BRAF V600E Dominant Clone. <i>Blood</i> , 2021 , 138, 4720-4720	2.2	
32	Association of high baseline ferritin with tocilizumab administration for CRS in relapsed/refractory multiple myeloma patients treated with bb2121 anti-BCMA CAR T cells.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15062-e15062	2.2	
31	Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study. <i>Blood</i> , 2018 , 132, 1991-1991	2.2	
30	MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21Cip1. <i>Blood</i> , 2018 , 132, 4464-4464	2.2	
29	Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting. <i>Blood</i> , 2018 , 132, 3253-3253	2.2	
28	Racial and insurance disparities in multiple myeloma management in a referral center.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18140-e18140	2.2	
27	Are two sites better than one?: Sites of care and quality of myeloma treatment.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18159-e18159	2.2	
26	Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect MM Registry. <i>Blood</i> , 2019 , 134, 1843-1843	2.2	
25	Medical resource utilization among multiple myeloma (MM) patients who were triple-exposed to a proteasome inhibitor, an immunomodulatory agent, and daratumumab.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e20539-e20539	2.2	
24	An Integrative Network Approach for Genomic Discovery and Personalized Therapy in Relapsed Multiple Myeloma. <i>Blood</i> , 2014 , 124, 3426-3426	2.2	
23	Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 1851-1851	2.2	
22	Progression-Free Survival in Third-Line Treatment of Relapsed/Refractory Multiple Myeloma Among Patients with Who Have Received Prior Bortezomib and Immunomodulatory Drugs. <i>Blood</i> , 2015 , 126, 3311-3311	2.2	

- 21 Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. *Blood*, **2016**, 128, 4414-4414 2.2
- 20 Aberrant a-to-I RNA Editing and Prognostic Impact of Adar in Multiple Myeloma Patients with 1q Amplification. *Blood*, **2016**, 128, 357-357 2.2
- 19 Mutation Burden in Multiple Myeloma Is Captured By Gene Expression Profiles. *Blood*, **2016**, 128, 4450-4450 2.2
- 18 Treatment outcomes and healthcare resource utilization (HRU) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) with lenalidomide (LEN) only or no maintenance: Connect MM registry.. *Journal of Clinical Oncology*, **2017**, 35, e19527-e19527 2.2
- 17 IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data. *Blood*, **2010**, 116, 1966-1966 2.2
- 16 Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib. *Blood*, **2010**, 116, 1942-1942 2.2
- 15 A Phase II Trial of TBL 12 Sea Cucumber Extract In Patients Withuntreated Asymptomatic Myeloma. *Blood*, **2010**, 116, 5042-5042 2.2
- 14 Outcomes of Plasma Cell Disorder Patients with Abnormal Hepatitis B and C Screening Tests Prior to Autologous Stem Cell Harvest and Transplantation. *Blood*, **2011**, 118, 4472-4472 2.2
- 13 Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study. *Blood*, **2011**, 118, 1875-1875 2.2
- 12 Outcomes of Salvage Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma Patients Relapsed After An Initial ASCT and Refractory to Bortezomib and Immunomodulatory Agents. *Blood*, **2011**, 118, 4484-4484 2.2
- 11 The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. *Blood*, **2011**, 118, 1024-1024 2.2
- 10 Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.. *Journal of Clinical Oncology*, **2012**, 30, 8035-8035 2.2
- 9 Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX).. *Journal of Clinical Oncology*, **2012**, 30, 8011-8011 2.2
- 8 Prognostic value of post-induction PET/CT in untreated multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).. *Journal of Clinical Oncology*, **2012**, 30, e21006-e21006 2.2
- 7 Patients with Newly Diagnosed Multiple Myeloma and a Gain of the Long Arms of Chromosome 1 Have Inferior Outcomes, Including Early Onset Extramedullary Disease, Despite the Use of Novel Triplet Regimens. *Blood*, **2012**, 120, 4996-4996 2.2
- 6 Lack of a Response by Serum Free Light Chains Performed Early Post Stem Cell Transplantation in Patients with Multiple Myeloma Predicts Inferior Progression Free and Overall Survival.. *Blood*, **2012**, 120, 3127-3127 2.2
- 5 Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). *Blood*, **2013**, 122, 3185-3185 2.2
- 4 Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma. *Blood*, **2013**, 122, 1965-1965 2.2

- 3 High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler). *Blood*, **2013**, 122, 1854-1854 2.2
- 2 Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m. *American Journal of Hematology*, **2020**, 95, E51-E54 7.1
- 1 Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone. *Blood*, **2020**, 136, 39-41 2.2